Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Oxytocics in Obstetric Practice

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Substances that stimulate contractions of the myometrium have found wide applications in present day obstetrics. Above all, fully synthetic, uterus-selective Prostaglandin analogues are used for preoperative priming of the cervix for termination of pregnancies in the first trimester as well as for the induction of abortions in the second trimester and have proved to have a much higher efficacy than Oxytocin. Because of the pharmacological synergism of their cervix ripening and myometrium stimulating activities, the local use of natural Prostaglandin E2 preparations (used intracervically as a gel or vaginally as a gel or as a tablet) is unequivocally superior to use of Oxytocin with its almost exclusive contraction stimulating activity for induction of labour, especially for women with an unripe cervix. In women with a ripe cervix, Oxytocin and Prostaglandins are equally effective with Oxytocin having the major advantage of its better controllability on continuous intravenous infusion (plasma elimination half-life of 10 minutes).

Over the past 50 years, the use of Oxytocin and ergot alkaloids preparations as prophylaxis against postpartum atonia has led to a marked reduction in maternal deaths. The same is true to a major extent for therapy for uterine atonia where the intravenous infusion of dinoprost is an indispensable and life-saving procedure after the failure of systemic administration of Oxytocin or ergot alkaloid preparations.

On the other hand, the administration of oxytocics can be accompanied by a wide range of adverse systemic and uterine effects and complications ranging from severe cardiovascular incidents with a fatal outcome through to the threat of uterine hyperstimulation with fetal asphyxia to uterine rupture. For these reasons, an adequate knowledge of the pharmacokinetics as well as the systemic and uterine activities and adverse effects of these substances is an essential prerequisite for every physician in evaluating differential indications for their use and adequate monitoring for mother and infant.

Of particular importance is the use of Prostaglandins for cervical priming prior to termination of pregnancies in the first and second trimesters and the use of native Prostaglandin and Oxytocin for inducing delivery in cases of fetal deaths as well as vital infants. Both substances play a decisive role at the beginning of delivery. Cervical priming and induction of contractions would not be conceivable without Prostaglandin and Oxytocin. The pharmacological properties of the 2 substances can be used in different ways for the induction of delivery. Oxytocin, ergot alkaloids and Prostaglandin are essential for the management of postpartum uterine atonia where their use often represents a decisive, life-saving intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bygdeman M, Berger GS, Keith LG. Prostaglandins and their inhibitors in clinical obstetrics and gynaecology. Lancaster: MTP Press, 1986

    Google Scholar 

  2. Egarter C, Husslein P. Biochemistry of myometrial contractility. Baillieres Clin Obstet Gynaecol 1992; 4: 755–69

    Google Scholar 

  3. Samuelson B, Goldyne M, Gangström E, et al. Prostaglandins and thromboxanes. Ann Rev Biochem 1987; 47: 997–1029

    Google Scholar 

  4. Carsten ME. Prostaglandins and cellular calcium transport in the pregnant human uterus. Am J Obstet Gynecol 1973; 117: 824–32

    PubMed  CAS  Google Scholar 

  5. Rath W, Osmers R, Adelmann-Grill BC, et al. Biochemical changes in human cervical connective tissue after intracervical application of Prostaglandin E2. Prostaglandins 1993; 45: 375–84

    PubMed  CAS  Google Scholar 

  6. Wakeling AE, Wyngarden LJ. Prostaglandin receptors in the human, monkey and hamster uterus. Endocrinology 1974; 95: 55–64

    PubMed  CAS  Google Scholar 

  7. Chan WY, Berezin I, Daniel EE. Effects of inhibition of prostaglandin synthesis on uterine Oxytocin receptor concentration and myometrial gap junction density in parturient rats. Biol Reprod 1988; 39: 1117–28

    PubMed  CAS  Google Scholar 

  8. Theobald PW, Rath W, Kuhnle H, et al. Histological and electron-microscopic examinations of collagenous connective tissue of the non-pregnant cervix, the pregnant cervix, and the pregnant prostaglandin-treated cervix. Arch Gynecol 1982; 231: 241–5

    PubMed  CAS  Google Scholar 

  9. Rath W, Osmers R, Adelmann-Grill BC, et al. Grundlagen der physiologischen und medikamentös induzierten Zervixreifung — Neuere morphologische und biochemische Befunde. Geburtshilfe Frauenheilkd 1990; 50: 657–64

    PubMed  CAS  Google Scholar 

  10. Osmers R, Rath W, Adelmann-Grill BC, et al. Origin of cervical collagenase during parturition. Am J Obstet Gynecol 1992; 166: 1455–60

    PubMed  CAS  Google Scholar 

  11. Junqueira LC, Zugaib M, Montes GS, et al. Morphologic and histochemical evidence for the occurrence of collagenolysis and for the role of neutrophilic polymorphonuclear leukocytes during cervical dilatation. Am J Obstet Gynecol 1980; 138: 272–81

    Google Scholar 

  12. Platz-Christensen JJ, Brandberg A, Wiquist N. Increased prostaglandin concentrations in the cervical mucus of pregnant women with bacterial vaginosis. Prostaglandins 1992; 43: 122–30

    Google Scholar 

  13. Lindblom B, Kallfelt B, Hahlin M, et al. Local Prostaglandin F2 alpha injection for termination of ectopic pregnancy. Lancet 1987; I: 776–7

    Google Scholar 

  14. Karim SMM. Clinical applications of Prostaglandins in obstetrics and gynaecology. Ann Acad Med Singapore 1982; 11: 493–502

    PubMed  CAS  Google Scholar 

  15. Schmidt-Gollwitzer K. Medikamentös induzierter Frühabort: Zyklus post abortum. In: Hepp H, Schüssler B, editors. Prostaglandine in Gynäkologie und Geburtshilfe. Berlin: Springer, 1981: 199–208

    Google Scholar 

  16. Rath W, Kuhn W. Prostaglandinen in Gynäkologie und Geburtshilfe. Arzneimitteltherapie 1988; 6: 111–21

    Google Scholar 

  17. Chen JK, Elder MG. Preoperative cervical dilatation by vaginal pessaries containing Prostaglandin E1 analogue. Obstet Gynecol 1983; 62: 339–42

    PubMed  CAS  Google Scholar 

  18. Welch C, Elder MG. Cervical dilatation with 16.16-Dimethyltrans-prostaglandin E1 methylester pessaries before surgical treatment of first trimester pregnancies. Br J Obstet Gynaecol 1982; 89: 849–52

    PubMed  CAS  Google Scholar 

  19. Kulenkampff D, Rath W, Kuhn W. Gemeprost Vaginalsuppositorien versus intrazervikale Sulproston-Gel-Applikation zum Zervixpriming im I. Trimenon. Geburtshilfe Frauenheilkd 1994; 54: 174–8

    PubMed  CAS  Google Scholar 

  20. Rabe T, Helk J, Kiesel L, et al. Anwendung eines neuen Scheidenzäpfchens: Prostaglandin-E1-Analog Gemeprost zur Zervixreifung vor Schwangerschaftsabbrüchen im ersten Trimester. Geburtshilfe Frauenheilkd 1985; 45: 393–401

    PubMed  CAS  Google Scholar 

  21. Christensen NJ, Bygdeman M, Green K. Comparison of different Prostaglandin analogues and laminaria for preoperative dilatation of the cervix in late first trimester abortion. Contraception 1983; 27: 51–61

    PubMed  CAS  Google Scholar 

  22. Kajanoja P, Mandelin M, Mäkilä UM, et al. A gemeprost vaginal suppository for cervical priming prior to termination of first trimester pregnancy. Contraception 1984; 29: 251–60

    PubMed  CAS  Google Scholar 

  23. Kajanoja P. Is preoperative cervical softening necessary in termination of pregnancy in nulliparous women? Zentralbl Gynakol 1990; 112: 589–91

    PubMed  CAS  Google Scholar 

  24. Krauß T, Rath W, Cunze T. Schwangerschaftsbeendigung im II. Trimenon durch serielle Applikation von Gemeprost-Vaginalsuppositorien. Geburtshilfe Frauenheilkd 1994; 54: 623–6

    PubMed  Google Scholar 

  25. Rath W, Krauß T, Kuhn W. Abortinduktion bei fortgeschrittenen Schwangerschaften. In: Künzel W, Kirschbaum M, editors. Gießener Gynäkologische Fortbildung. Berlin, Heidelberg, New York: Springer, 1993: 166–75

    Google Scholar 

  26. Rath W. Die Anwendung von Prostaglandinen zur Schwangerschaftsbeendigung im I. und II. Trimenon. Wien Klin Wochenschr 1987; 99: 741–51

    PubMed  CAS  Google Scholar 

  27. Andersen LF, Poulsen HK, Sorensen SS, et al. Termination of second trimester pregnancy with gemeprost vaginal pessaries and intraamniotic PGF2α. Eur J Obstet Gynecol Reprod Biol 1989; 31: 1–7

    PubMed  CAS  Google Scholar 

  28. Sakomoto S, Satoh K, Nishiya I, et al. Abortifacient effect and uterine cervix-dilating action of 16, 16-dimethyl-trans-delta 2 PGE1-methyl ester (ONO 802) in the form of a vaginal suppository (a randomized, double-blind controlled study in the second trimester of pregnancy). Prostaglandins Leukot Med 1982; 9: 349–59

    Google Scholar 

  29. Querido L, Haspels AA. Late second trimester abortion with 16,16-dimethyl-trans-delta 2-PGE1 methyl ester (Gemeprost). Contraception 1990; 42: 43–9

    PubMed  CAS  Google Scholar 

  30. Thong KJ, Baird DT. An open study comparing two regimens of gemeprost for the termination of pregnancy in the second trimester. Acta Obstet Gynecol Scand 1992; 71: 191–6

    PubMed  CAS  Google Scholar 

  31. Di Lieto A, Catalano D, Albano G, et al. Uterine motility and cervical ripening in second trimester elective abortion by two different PGE analogues. Clin Exp Obstet Gynecol 1991; 18: 251–9

    PubMed  Google Scholar 

  32. Winkler M, Rath W Aktuelles Vorgehen bei der vorzeitigen Schwangerschaftsbeendigung mit Prostaglandinen im II. und III. Trimenon. Z Geburtshilfe Neonatal 1997; 201: 39–43

    CAS  Google Scholar 

  33. Cameron IT, Michie AF, Baird DT. Prostaglandin-induced pregnancy termination: further studies using gemeprost vaginal pessaries in the early second trimester. Prostaglandins 1987; 34: 111–7

    PubMed  CAS  Google Scholar 

  34. Rabe T, Basse H, Thuro H, et al. Effect of PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester. Geburtshilfe Frauenheilkd 1987; 47: 324–31

    PubMed  CAS  Google Scholar 

  35. Norman JE, Thong KJ, Baird DT. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991; 338: 1233–6

    PubMed  CAS  Google Scholar 

  36. Jan JK, Missile DR. A comparison of intravaginal misoprostol with Prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 1994; 331: 290–3

    Google Scholar 

  37. Windrow R, Beneath K, Muddle W, et al. Oral administration of misoprostol for labor induction: a randomized controlled trial. Obstet Gynecol 1997; 89: 392–7

    Google Scholar 

  38. Sanchez-Ramos L, Chintz AM, Wears AL, et al. Misoprostol for cervical ripening and labor induction: a meta-analysis. Obstet Gynecology 1997; 89: 633–42

    CAS  Google Scholar 

  39. Gars RE, Quirked CF. Misoprostol: a Prostaglandin E1 analogue. Clin Pharm 1989; 8: 627–44

    Google Scholar 

  40. Karim A. Antiulcer Prostaglandin misoprostol: single and multiple dose pharmacokinetic profile. Prostaglandins 1987; 33 Suppl.: 40–50

    PubMed  CAS  Google Scholar 

  41. El-Refaey H, Templeton A. Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and of their effect on blood pressure. Br J Obstet Gynaecol 1994; 101: 792–6

    PubMed  CAS  Google Scholar 

  42. Ranta H, Tuimala R. Second trimester abortion with vaginal gemeprost or intravenous sulprostone. J Obstet Gynaecol 1991; 11: 227–8

    Google Scholar 

  43. Müller T, Backe J, Rempen A. Vorzeitige Schwangerschaftsbeendigung im II. und III. Trimenon. Geburtshilfe Frauenheilkd 1996; 56: 234–8

    PubMed  Google Scholar 

  44. Mink D, Heiss C, Rothbrust S, et al. Vergleich von Dinoproston-Gel und Gemeproston-Suppositorien zur Abortinduktion im zweiten und dritten Trimenon. Zentralbl Gynakol 1995; 117: 263–8

    PubMed  CAS  Google Scholar 

  45. Kjolhede P, Dahle LA, Matthiesen L, et al. An open prospective randomized study of dinoproston and gemeprost in second trimester legal abortions. Acta Obstet Gynecol Scand 1994; 73: 316–20

    PubMed  CAS  Google Scholar 

  46. Guidotti RJ, Grimes DA, Cates W Jr. Fetal amniotic fluid embolism during legally induced abortion. Am J Obstet Gynecol 1981; 141: 257–61

    PubMed  CAS  Google Scholar 

  47. Meyer WJ, Benton SL, Hoon TJ, et al. Acute myocardial infarction associated with Prostaglandin E2. Am J Obstet Gynecol 1991; 165: 359–60

    PubMed  CAS  Google Scholar 

  48. Wischnik A, Rath W. Indikationen zur Geburtseinleitung unter besonderer Berücksichtigung der Prostaglandine. In: Rath W, editor. Fortschritte in der medikamentösen Geburtseinleitung. Mülheim: HUF-Verlag, 1996: 47–62

    Google Scholar 

  49. Bishop EH. Pelvic scoring for elective induction. Obstet Gynecol 1964; 24: 266–8

    PubMed  CAS  Google Scholar 

  50. Goeschen K, Saling E. Induktion der Zervixreife mit Oxytocinversus PGF2α-Infusion versus PGE2-Gel intrazervikal bei Risikoschwangeren mit unreifer Zervix. Geburtshilfe Frauenheilkd 1982; 42: 810–6

    PubMed  CAS  Google Scholar 

  51. Davies NJ, Martindale E, Haddad NG. Cervical ripening with oral Prostaglandin E2 tablets and the effect of the latent period in patients with premature rupture of the membranes at term. J Obstet Gynecol 1991; 11: 405–8

    Google Scholar 

  52. Keirse MJ. Therapeutic uses of Prostaglandins. Baillieres Clin Obstet Gynaecol 1992; 6: 787–807

    PubMed  CAS  Google Scholar 

  53. Kieback DG, Zahradnik H-P, Quass L, et al. Clinical evaluation of endocervical prostaglandin-E2-triacetin-gel for preinduction cervical softening in pregnant women at term. Prostaglandins 1986; 32: 81–5

    PubMed  CAS  Google Scholar 

  54. Schneider KTM, Lüftner D, Rath W. Geburtseinleitung mit Prostaglandinen - Nutzen und Risiken. In: Rath W, editor. Fortschritte in der medikamentösen Geburtseinleitung. Mülheim: HUF-Verlag, 1996: 63–83

    Google Scholar 

  55. Goeschen K, Mesrogli M, Rosswog V, et al. Vorzeitiger Blasensprung in Terminnähe: Abwarten oder Handeln? Z Geburtshilfe Perinatol 1989; 193: 16–21

    PubMed  CAS  Google Scholar 

  56. Goeree R, Hannah M, Hewson S, et al. Cost-effectiveness of induction of labour versus serial antenatal monitoring in the Canadian multicentre postterm pregnancy trial. Can Med Assoc J 1995; 152: 1445–50

    CAS  Google Scholar 

  57. Dennemark N, Rath W. Lokale Prostaglandintherapie zur Geburtseinleitung bei Risikoschwangerschaften. Gynakol Prax 1985; 9: 657–67

    Google Scholar 

  58. Egarter C, Husslein PW, Rayburn WF. Uterine Hyperstimulation after low-dose Prostaglandin E2 therapy: tocolytic treatment in 181 cases. Am J Obstet Gynecol 1990; 163: 794–6

    PubMed  CAS  Google Scholar 

  59. Schneider KTM, Lüftner D, Rath W. Die Geburtseinleitung mit Prostaglandinen - Nutzen und Risiken: In: Somville T, Rath W, editors. Prostaglandine. Aktualisierte Anwendung in Geburtshilfe und Gynäkologie. Gräfelfing: Socio-Medico-Verlag, 1993: 67–88

    Google Scholar 

  60. Rayburn WF. Prostaglandin E2 gel for cervical ripening and induction of labor: a critical analysis. Am J Obstet Gynecol 1989; 160: 529–34

    PubMed  CAS  Google Scholar 

  61. Noah NL, DeCoster JM, Fraser TJ, et al. Preinduction cervical softening with endocervical PGE2 gel. Acta Obstet Gynecol Scand 1987; 66: 3–7

    PubMed  CAS  Google Scholar 

  62. Osmers R, Rath W. Anwendung von Prostaglandinen zur Geburtseinleitung. Gynakol Prax 1986; 10: 621–31

    Google Scholar 

  63. Phuapradit W, Herabutya Y, Saropala. Uterine rupture and labor induction with Prostaglandins. J Med Assoc Thai 1993; 76: 292–5

    PubMed  CAS  Google Scholar 

  64. Maymon R, Haimovich L, Shulman A, et al. Third trimester uterine rupture after Prostaglandin E2 use for labor induction. J Reprod Med 1992; 37: 449–52

    PubMed  CAS  Google Scholar 

  65. Azem F, Jaffa A, Lessing JB, et al. Uterine rupture with the use of a low-dose vaginal PGE2 tablet. Acta Obstet Gynecol Scand 1993; 72: 316–7

    PubMed  CAS  Google Scholar 

  66. Maymon R, Shulman A, Pomeranz M, et al. Uterine rupture at term pregnancy with the use of intracervical Prostaglandin E2 gel for induction of labor. Am J Obstet Gynecol 1991; 165: 368–70

    PubMed  CAS  Google Scholar 

  67. Husslein P, Egarter C, Sevalda P, et al. Geburtseinleitung mit 3 mg Prostaglandin-E2-Vaginaltabletten: Eine Renaissance der programmierten Geburt? Geburtshilfe Frauenheilkd 1986; 46: 83–7

    PubMed  CAS  Google Scholar 

  68. Kofier E, Egarter C, Husslein P. Erfahrungen bei 2 149 Geburtseinleitungen mit 3 mg Prostaglandin-E2-Vaginaltabletten. Geburtshilfe Frauenheilkd 1986; 46: 863–8

    Google Scholar 

  69. Dennemark N. Nicht selektive Geburtseinleitung mit Minprostin®-E2-Vaginaltabletten. Med Report 1989; 1: 2–3

    Google Scholar 

  70. Bremme K, Eneroth P, Kindahl H. 15-Keto-13, 14-dihydroprostaglandin F2α and prolactin in maternal and cord blood during Prostaglandin E2 or Oxytocin therapy for labor induction. J Perinat Med 1987; 15: 143–51

    PubMed  CAS  Google Scholar 

  71. Fuchs AR, Goeschen K, Husslein P, et al. Oxytocin and the initiation of human parturition: III: plasma concentrations of Oxytocin and 13,14-dihydro-15-keto-prostaglandin F2α in spontaneous and oxytocin-induced labor at term. Am J Obstet Gynecol 1983; 147: 497–503

    PubMed  CAS  Google Scholar 

  72. McLaren M, Greer IA, Smith JR, et al. Maternal plasma bicycling PGE2 levels following vaginal administration of prostaglandin E2 pessaries in full term pregnancies. Prog Clin Biol Res 1987; 242: 199–203

    PubMed  CAS  Google Scholar 

  73. Reichel K, Husslein P, Goeschen K, et al. Untersuchungen zur Resorption von PGE2 nach unterschiedlicher Applikation zur Zervixreifung und zur Geburtseinleitung. Wien Klin Wochenschr 1985; 97: 500–3

    PubMed  CAS  Google Scholar 

  74. Lyndrup J. Induction of labour by PGE2 and other local methods. Dan Med Bull 1995; 42: 227–43

    PubMed  CAS  Google Scholar 

  75. Kimball FA, Ruppel PL, Noah ML, et al. The effect of endocervical PGE2 gel (prepidil) on plasma levels of 13, 13-dihydro-15-keto PGE2 in women at term. Prostaglandins 1986; 32: 527–37

    PubMed  CAS  Google Scholar 

  76. Chin SC, Murray A, Maresh MJA, et al. The use of prostaglandin E2 gel for induction of labour in nulliparous patients with a Bishop score of 4 or less. J Obstet Gynaecol 1989; 10: 103–5

    Google Scholar 

  77. Hales KA, Rayburn WF, Turnbull HD, et al. Double blind comparison of intracervical and intravaginal Prostaglandin E2 for cervical ripening and induction of labor. Am J Obstet Gynecol 1994; 171: 1087–91

    PubMed  CAS  Google Scholar 

  78. Mahmood TA. A prospective comparative study on the use of Prostaglandin E2 gel (2mg) and Prostaglandin E2 tablet (3mg) for the induction of labour in primigravid women with unfavourable cervices. Eur J Obstet Gynecol Reprod Biol 1989; 33: 169–75

    PubMed  CAS  Google Scholar 

  79. Greer IA, McLaren M, Calder AA. Vaginal administration of PGE2 for induction of labour stimulates endogenous PGF2α production. Acta Obstet Gynecol Scand 1990; 69: 621–5

    PubMed  CAS  Google Scholar 

  80. Embrey MP, Graham NB, McNeill ME. Induction of labour with a sustained-release Prostaglandin E2 vaginal pessary. BMJ 1980; 281: 901–2

    PubMed  CAS  Google Scholar 

  81. Embrey MP, MacKenzie IZ. Labour induction with a sustained release Prostaglandin E2 polymer vaginal pessary. J Obstet Gynaecol 1985; 6: 38–41

    Google Scholar 

  82. MacKenzie IZ, Castle B, Mountford L, et al. Prostaglandin release from preparations used vaginally for the induction of labour. Prostaglandins 1987; 34: 939–46

    PubMed  CAS  Google Scholar 

  83. Taylor AVG, Boland J, MacKenzie IZ. The concurrent in vitro and in vivo release of PGE2 from a controlled release hydrogel polymer pessary for cervical ripening. Prostaglandins 1990; 40: 89–98

    PubMed  CAS  Google Scholar 

  84. Khouzam MN, Ledward RS. Difficulties with controlled release prostglandin E2 pessaries. Lancet 1990; 336: 119

    Google Scholar 

  85. Bex P, Gunasekera PC, Phipps JH. Difficulties with controlled release prostglandin E2 pessaries. Lancet 1990; 336: 119

    Google Scholar 

  86. Norman M, Ekman G. Preinductive cervical ripening with prostaglandin E2 in women with one previous cesarean. Acta Obstet Gynecol Scand 1992; 71: 351–5

    PubMed  CAS  Google Scholar 

  87. Behrens O, Goeschen K, Jakob H, et al. Geburtseinleitung mit Prostaglandin-E2-Gel bei Zustand nach Sectio. Geburtshilfe Frauenheilkd 1994; 54: 144–50

    PubMed  CAS  Google Scholar 

  88. MacKenzie IZ, Bradley S, Embrey MP. Vaginal Prostaglandins and labour induction for patients previously delivered by caesarean section. Br J Obstet Gynaecol 1984; 91: 7–10

    PubMed  CAS  Google Scholar 

  89. Schneider KTM, Lüftner D, Rath W, et al. Prostaglandin-Geburtseinleitung bei Zustand nach Sectio caesarea. Zentralbl Gynakol 1994; 116: 461–7

    PubMed  CAS  Google Scholar 

  90. MacKenzie IZ. Prostaglandin induction and the scarred uterus. In: Keirse MJNC, Elder MG, editors. Induction of labour: special issues. 2nd European Congress on Prostaglandins in Reproduction. 1991 May 3, The Hague. Amsterdam: Excerpta Medica, 1991: 29–39

    Google Scholar 

  91. Flamm BL, Lim OW, Jones C, et al. Vaginal birth after cesarean section: results of a multicenter study. Am J Obstet Gynecol 1988; 158: 1079–84

    PubMed  CAS  Google Scholar 

  92. Chattopadhyay SK, Sengupta BS, Edrees YB. Intracervical application of Prostaglandin E2 tablets for elective induction of labor in grand multiparae: a prospective controlled study. Eur J Obstet Gynaecol Reprod Biol 1986; 22: 7–15

    CAS  Google Scholar 

  93. Wing DA, Rahall A, Jones MM, et al. Misoprostol: an effective agent for cervical ripening and labor induction. Am J Obstet Gynecol 1995; 172: 1811–6

    PubMed  CAS  Google Scholar 

  94. Wing DA, Jones MM, Rahall A, et al. A comparison of misoprostol and Prostaglandin E2 gel for preinduction cervical ripening and labor induction. Am J Obstet Gynecol 1995; 172: 1804–10

    PubMed  CAS  Google Scholar 

  95. Sanchez-Ramos L, Kaunitz AM, Del Valle GO, et al. Labor induction with the Prostaglandin E1 methyl analogue misoprostol versus Oxytocin: a randomized trial. Obstet Gynecol 1993; 81: 332–6

    PubMed  CAS  Google Scholar 

  96. Hofmeyr GJ. Misoprostol administered vaginally for cervical ripening and labour induction with a viable fetus. The Cochrane Library 1998; 1

  97. Prendiville W, Elbourne D, Chalmers I. The effects of routine oxytocic administration in the management of the third stage of labour: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1988; 95: 3–16

    PubMed  CAS  Google Scholar 

  98. Zahradnik HP, Quaas L, Breckwoldt M. Uterusatonie - Wandel derBehandlungsmethoden in den letzten 20 Jahren. In: Haller U, Kubli F, Husslein P, editors. Prostaglandine in Geburtshilfe und Gynäkologie. Berlin: Springer, 1988: 220–9

    Google Scholar 

  99. Goedicke HD. Treatment of post partum atonic haemorrhage with the prostaglandin-E2 derivative Nalador®: results of a multicentre trial. In: Egarter C, Husslein P, editors. Post partum uterine atonia. Vienna: Facultas, 1989: 41–9

    Google Scholar 

  100. Rath W. Therapeutisches Vorgehen bei atonischer Nachblutung. Kliniksarzt 1990; 19: 33–7

    Google Scholar 

  101. Heinzl S. Postpartale Uterusatonie und Prostaglandine. In: Haller U, Kubli F, Husslein P, editors. Prostaglandine in Geburtshilfe und Gynäkologie. Berlin: Springer, 1988: 207–15

    Google Scholar 

  102. Kilpatrick AW, Thorburn J. Severe hypotension due to intramyometrial injection of Prostaglandin E2. Anaesthesia 1990; 45: 848–9

    PubMed  CAS  Google Scholar 

  103. Popat MT, Suppiah N, White JB. Cardiac arrest following intramyometrial injection of prostglandin E2. Anaesthesia 1991; 46: 236

    PubMed  CAS  Google Scholar 

  104. Litschgi M. Prostaglandins and post partum uterine atonia. In: Egarter C, Husslein P, editors. Post partum uterine atonia. Vienna: Facultas, 1989: 61–8

    Google Scholar 

  105. Keirse MJNC. Treatment of post partum uterine hypotonia with Prostaglandins. In: Egarter C, Husslein P, editors. Postpartum uterine atonia. Vienna: Facultas, 1989: 25–32

    Google Scholar 

  106. Hogerzeil HV, Walker GJA, de Goeje MJ. Stability of injectable oxytocics in tropic climates. Geneva: World Health Organisation, 1993

    Google Scholar 

  107. El-Refaey H, O’Brien P, Morafa W, et al. Misoprostol for third stage of labour. Lancet 1996; 347: 1257

    PubMed  CAS  Google Scholar 

  108. Zeeman GG, Khan-Dawood FS, Dawood MY. Oxytocin and its receptor in pregnancy and parturition: current concepts and clinical implications. Obstet Gynecol 1997; 89: 873–83

    PubMed  CAS  Google Scholar 

  109. Fuchs A-R, Fuchs F, Husslein P, et al. Oxytocin receptors and human parturition: a dual role for Oxytocin in the initiation of labor. Science 1982; 215: 1396–8

    PubMed  CAS  Google Scholar 

  110. Fuchs A-R, Fuchs F, Husslein P, et al. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984; 150: 734–41

    PubMed  CAS  Google Scholar 

  111. Leake RD, Weitzman RE, Fisher DA. Pharmacokinetics of Oxytocin in the human subject. Obstet Gynecol 1980; 56: 701–4

    PubMed  CAS  Google Scholar 

  112. Seitchik J, Castillo M. Oxytocin augmentation of dysfunctional labor: II: uterine activity data. Am J Obstet Gynecol 1983; 145: 526–9

    PubMed  CAS  Google Scholar 

  113. Kauffels W, Merrill DC, Nybiel J, et al. Die Geburtseinleitung mit Oxytozin-Nutzen und Risiken. In: Rath W, editor. Fortschritte in der medikamentösen Geburtseinleitung. Mülheim: HUF-Verlag, 1996: 85–96

    Google Scholar 

  114. Taylor RW, Taylor M. Misuse of Oxytocin in labour. Lancet 1988; I: 352–00

    Google Scholar 

  115. ACOG technical bulletin: induction of labor. No. 217, Dec 1995. Int J Gynaecol Obstet 1996; 53: 65-72

    Google Scholar 

  116. Awais GM, Lebherz TB. Ruptured uterus, a complication of Oxytocin induction and high parity. Obstet Gynecol 1970; 36: 465–72

    PubMed  CAS  Google Scholar 

  117. Orhue AAE. A randomised trial of 45 minutes and 15 minutes incremental Oxytocin infusion regimes for the induction of labour in women of high parity. Br J Obstet Gynaecol 1993; 100: 126–9

    PubMed  CAS  Google Scholar 

  118. Cummiskey KC, Gall SA, Dawood MY. Pulsatile administration of Oxytocin for augmentation of labor. Obstet Gynecol 1989; 74: 869–72

    PubMed  CAS  Google Scholar 

  119. Kranzfelder D. Nachgeburtsperiode. In: Kiinzel W, Wulf K-H, editors. Klinik der Frauenheilkunde und Geburtshilfe. Munich: Urban & Schwarzenberg, 1996: 301–15

    Google Scholar 

  120. Elbourne D, Prendiville W, Chalmers I. Choice of oxytocic preparation for routine use in the management of the third stage of labour: an overview of the evidence from controlled trials. Br J Obstet Gynaecol 1988; 95: 17–30

    PubMed  CAS  Google Scholar 

  121. Carey M. Adverse cardiovascular sequelae of ergometrine. Br J Obstet Gynaecol 1993; 100: 865

    PubMed  CAS  Google Scholar 

  122. Dua JA. Postpartum eclampsia associated with ergometrine maleate administration. Br J Obstet Gynaecol 1994; 101: 72–3

    PubMed  CAS  Google Scholar 

  123. McDonald S, Prendiville WJ, Elbourne D. Prophylactic syntometrine vs Oxytocin in the third stage of labour. The Cochrane Library 1998; 1

  124. Symes JB. A study on the effect of ergometrin on serum prolactin levels following delivery. J Obstet Gynaecol 1984; 5: 36–8

    Google Scholar 

  125. Pauli JD, Ratten GJ. Ergometrine and third stage blood loss. Med JAust 1977; 1: 178–9

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department for Obstetrics and Gynecology, University Hospital, Technical University, D-52057, Aachen, Germany

    Matthias Winkler & Werner Rath

Authors
  1. Matthias Winkler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Werner Rath
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winkler, M., Rath, W. A Risk-Benefit Assessment of Oxytocics in Obstetric Practice. Drug-Safety 20, 323–345 (1999). https://doi.org/10.2165/00002018-199920040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920040-00003

Keywords

Search

Navigation